RE:RE:RE:RE:RE:ONC/Y and the FDAQuentin30 it is difficult to be completely independant when a portion of your operating review relies on the companies you're to be overseeing. This was particularly evident with Pfzier when FDA attempted to withhold test results from their covid vaccine for decades until a judge ordered a release with in a year. I had meant to mention that an AA is unlikely because of such a small test population, which someoneelse has mentioned also. It is discouraging seeing the scenario play out again with this company that we have experienced for years now. There is just no evidence of any BP being interested in a buyout.